Zhiyu Li
Professor of Medicinal Chemistry; Vice Dean of Institute of the College of Pharmacy.
Education
BA, MA, PhD, China Pharmaceutical University;
Postdoctor, University della Carabulia
Profile
Zhiyu Li group has focused on the following two directions: 1) The synthesis of natural products and the structural optimization; 2) The design and synthesis of novel drugs. In recent years, he has been mainly engaged in the discovery and development of new antitumor drugs research. Remarkable achievements has been made in structural modification of bioactive natural products, and discovery of novel antitumor drugs.
Recently, Zhiyu Li is in charge of two national natural science foundation projects, and two natural foundation projects of Jiangsu province. In addition, he has participated in three major national new drug research of major science and technology programs. Besides, Zhiyu Li also conducted fifteen horizontal topic research. In the research of natural product Wogonin which belongs to national class 1.1 drug, he is responsible for the part of synthetic technology. The project is now approved for phase I and II clinical studies. And he has applied for more than 20 patents as the first inventor and 19 patents has been authorized. In the past three years, he has published more than 30 academic papers (SCI).
Contact Information
zhiyuli@cpu.edu.cn Tel.: 13951678592
Main Research Directions
1. A novel androgen receptor antagonist research for malignant prostate cancer; National Natural Science Foundation of China, approval No. 213722602.
2. GPIIb / IIIa receptor antagonist research with natural polypeptide AAP as the lead compound; National Natural Science Foundation of China, approval No. 81273375.
3. A novel Indoleamine 2,3-dioxygenase (IDO) inhibitor research based on tumor immune regulation mechanism.
4. Design, synthesis and biological study of novel selective CDK9 inhibitors.
Selected publications
1. Zhouling Xie, Benimana Oscar, Yi Kong**, Zhiyu Li*, Design, synthesis and evaluation of novel 2-amino-3-(naphth-2-yl)propanoic acid derivatives as potent inhibitors of platelet aggregation, European Journal of Medicinal Chemistry, 2016, Accept.
2. Raoling Ge, Qian Zhao, Zhouling Xie, Lu Lu, Qinglong Guo, Zhiyu Li*, Li Zhao*, Synthesis and Biological Evaluation of 6-fluoro-3-phenyl-7-piperazinyl Quinolone Derivatives as Potential Topoisomerase I Inhibitors, European Journal of Medicinal Chemistry, 122 (2016) 465-474.
3. Zhouling Xie, Yu Chen, Pengfei Xu, Youli Zhou, Qian Zhao, He Jiao, Zhiyu Li*, Design, synthesis and bioevaluation of 1H-indole-4-carboxamide derivatives as potent Poly (ADP-ribose) polymerase-1 inhibitors, RSC Advance, 2016, 6, 80784–80796.
4. Zhouling Xie, Sen Feng, Ying Wang, Chen Cao, Jing Huang, Yahui Chen,Yi Kong **, Zhiyu Li*, Design, synthesis of novel tryptophan derivatives for antiplateletaggregation activity based on tripeptide pENW (pGlu-Asn-Trp) European Journal of Medicinal Chemistry 102 (2015) 363-374
5. Qian Zhao, Xi Xu, Zhouling Xie, Xiao Liu, Qidong You, Qinglong Guo, Yi Zhong, Zhiyu Li* Design, synthesis and biological evaluation of 3-substituted indenoisoquinoline derivatives as topoisomerase I inhibitors Bioorganic & Medicinal Chemistry Letters 26 (2016) 1068–1072.
6. Tinghan Li, Tianwei Weng, Minzan Zuo, Zhihui Wei, Ming Chen, Zhiyu Li*, Recent progress of cyclin-dependent kinase inhibitors as potential anticancer agents, Future Medicinal Chemistry, 2016, Accept.
7. Qian Zhao, Xi Xu, Zhouling Xie, Xiao Liu, Qidong You, Qinglong Guo, Yi Zhong, Zhiyu Li* Design, synthesis and biological evaluation of 3-substituted indenoisoquinoline derivatives as topoisomerase I inhibitors Bioorganic & Medicinal Chemistry Letters 26 (2016) 1068–1072.
8. Minzan Zuo, Xi Xu, Tinghan Li, Raoling Ge, Zhiyu Li*, Progress in the mechanism and drug development of castration-resistant prostate cancer, Future Med. Chem. (2016) 5(2), 1756–8919.
9. Tianze Jiang‡, Yingying Sun‡, Zhichao Yin, Sen Feng, Liping Sun & Zhiyu Li*, Research progress of indoleamine 2,3-dioxygenase inhibitors Future Med. Chem. (2015) 7(2), 185–201
10. Yi Kong*, Ying Wang, Wei Yang, Zhouling Xie, Zhiyu Li* LX0702, a novel snake venom peptide derivative, inhibits thrombus formation via affecting the binding of fibrinogen with GPIIb/IIIa. Journal of Pharmacological Sciences 127 (2015) 462-466
11. Yahui Chen, Ying Wang, Zhouling Xie, Xin Ming, Zhiyu Li**, Yi Kong*, A tryptophan derivative TD-26 attenuates thrombus formation by inhibiting both PI3K/Akt signaling and binding of fibrinogen to integrin aIIbb3 Biochemical and Biophysical Research Communications 465 (2015) 516-522
12. Zhouling Xie, Chen Cao, Sen Feng, Jing Huang, Zhiyu Li*, Progress in the research of GPIIb/IIIa antagonists. Future Med. Chem. (2015) 7(9), 1149–1171
